Retrospective Evaluation of CroFab - Efficacy in Severe Envenomation
Sponsored by BTG International Inc.
About this trial
Last updated 3 years ago
Study ID
Status
Type
Placebo
Accepting
Not accepting
Trial Timing
Ended 20 years ago
What is this trial about?
What are the participation requirements?
Inclusion Criteria
- Must involve treatment of a human patient with CroFab between January 1, 2002 and December 31, 2004 - The record must contain all of the following: 1. Clinical signs/symptoms prior to the first dose of antivenom, 2. Documentation of all doses of antivenom used to treat the patient, 3. Indication of whether or not initial control was achieved with antivenom. To be included in the Efficacy Evaluable Population (EEP) in the current analysis, each record must meet the following criteria: - Must contain enough information to calculate a severity score based on the 7-point severity scale. - All records were included in the Safety Population in the current analysis.
Exclusion Criteria
- Any cases identified that do not meet the inclusion criteria were excluded, including cases not treated with CroFab.